Guideline and consensus literature addressing outpatient or community-based initiation of step-up dosing (SUD) for T-cell–engaging bispecific antibody therapy in multiple myeloma emphasizes patient selection, toxicity monitoring, infection prophylaxis, caregiver support, and institutional readiness rather than prospective comparative data specific to community hospital initiation. The International Myeloma Working Group Immunotherapy Committee consensus review provides broader clinical-practice guidance for bispecific antibody use in relapsed/refractory multiple myeloma, describing these agents as therapies that simultaneously bind CD3 on T cells and a tumor-cell surface antigen, and noting that cytokine release syndrome (CRS) is generally grade 1 or 2 and typically occurs during SUD or the first full dose; the review also states that initial clinical trials required inpatient monitoring during SUD and/or first full dosing, while outpatient dosing and tocilizumab prophylaxis are being explored in selected real-world centers, with local standard operating procedures recommended to optimize care. Building on this broader guidance, the European modified Delphi consensus specifically addresses transition from academic hospitals to community-based centers and outpatient SUD for BCMA-targeting bispecific antibodies, recommending that outpatient SUD be restricted to clinically stable patients with low tumor burden, stable disease and organ function, ECOG performance status 0–2, and reliable caregiver support, and that administration occur only in centers with staff trained in CRS and immune effector cell–associated neurotoxicity syndrome recognition and management, urgent laboratory access, clear escalation pathways, access to tocilizumab and corticosteroids, infection prophylaxis and immunoglobulin monitoring, patient/caregiver education, and structured communication between academic and community teams. [1], [2]
A 2024 meta-analysis evaluated the efficacy and safety of bispecific antibody therapy in relapsed or refractory multiple myeloma across 14 prospective phase 1 or 2 clinical trials comprising 1,473 patients, including 829 treated with BCMA-targeted bispecific antibodies and 644 treated with non-BCMA-targeted bispecific antibodies. The analysis included teclistamab, elranatamab, linvoseltamab, alnuctamab, talquetamab, cevostamab, RG6234, ISB-1342, and other bispecific antibody regimens administered by intravenous or subcutaneous routes, but it did not specifically evaluate initiation of step-up dosing in the outpatient setting or in community hospitals. Across the included trials, the pooled overall response rate was 61%, with a higher overall response rate reported for non-BCMA-targeted versus BCMA-targeted bispecific antibodies (74% vs 54%; P<0.01). Cytokine release syndrome occurred at similar rates between BCMA-targeted and non-BCMA-targeted therapies for any grade events (64% vs 66%; P=0.84) and grade ≥3 events (1% vs 1%; P=0.36), while infections were also comparable for any grade events (47% vs 49%; P=0.86) and grade ≥3 events (24% vs 20%; P=0.06). The authors reported that common adverse events included cytokine release syndrome, infections, and neutropenia, with cytokine release syndrome generally limited to low-grade events; however, the publication does not provide evidence specific to outpatient step-up dosing implementation or feasibility in the community hospital setting. [3]
A 2026 review described the implementation of an outpatient B-cell maturation antigen–directed bispecific antibody step-up dosing program at New England Cancer Specialists, a nationally accredited, independent community oncology practice with sites in Maine and New Hampshire serving a rural patient population. The article reviewed FDA-approved BCMA-CD3 bispecific antibodies for relapsed or refractory multiple myeloma, including teclistamab, elranatamab, and linvoseltamab, and outlined the rationale for outpatient step-up dosing as a strategy to reduce health care resource utilization, improve patient experience, and expand treatment access. The New England Cancer Specialists model incorporated standardized patient eligibility screening, a multidisciplinary treatment team, extended patient and care partner education, required proximity to the clinic after step-up dosing, home vital-sign monitoring equipment, scheduled post-dose toxicity assessment calls, electronic medical record–based order sets and toxicity documentation, anti-infective prophylaxis, and collaboration with a local hospital for management of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome when needed. The program required patients and caregivers to remain within 30 minutes of the clinic for 48 hours after each step-up dose and included structured workflows for toxicity monitoring and escalation. The authors reported that the first patient treated entirely through the program received elranatamab, that eligible patients continued to receive elranatamab as a fully outpatient service, and that the average time from eligibility decision to bispecific antibody treatment initiation was approximately 3 weeks. The authors concluded that the New England Cancer Specialists experience demonstrates the potential implementation of a fully community-based bispecific antibody step-up dosing program, particularly for patients in rural areas, while emphasizing the need for continued research to optimize outpatient administrations workflows and infrastructure. [4]
A 2026 structured narrative review evaluated outpatient step-up dosing of bispecific antibodies for relapsed or refractory multiple myeloma and provides a practice-oriented framework relevant to literature review on ambulatory initiation of BiTE-like therapy. The review synthesized prescribing information, clinical safety reports, expert guidance, implementation literature, and nursing supportive-care evidence through March 2026, emphasizing that outpatient initiation should not be considered a simple transfer of inpatient dosing to the clinic, but rather a selective high-acuity care model requiring alignment of product-specific toxicity kinetics, patient-level biologic vulnerability, caregiver reliability, communication capacity, geography, and institutional rescue capability. The authors noted that currently approved agents differ by target antigen, route of administration, step-up schedule, premedication, cytokine release syndrome timing, monitoring requirements, and long-term toxicity patterns, supporting product-specific observation windows, home-surveillance instructions, and escalation thresholds. For community, rural, or resource-limited settings, the review cautioned that evidence from high-volume centers may not generalize and described resource-stratified approaches, including inpatient, hybrid, near-center outpatient, and highly selected fully outpatient models, with inpatient or hybrid initiation favored when after-hours hematology coverage, emergency department preparedness, rapid access to CRS-directed therapy, transport, caregiver support, or inpatient/ICU backup is limited. The authors concluded that prospective validation of outpatient eligibility criteria, remote monitoring, nursing-sensitive outcomes, and resource-stratified pathways is needed. [5]